Also, aside form the liver disease black box warni

Quote:

---

Also, aside form the liver disease black box warning) do we have an understanding of how much more clinically effective leronlimab is likely to be than than maraviroc in various disease patholigies

---

100% receptor occupancy for leronlimab vs. 84% for maraviroc. Maraviroc also binds allosterically which means it changes the shape of CCR5 to stop binding of proteins. But the shape changing is not the most effective, it allows the HIV virus to bind sometimes even when the CCR5 receptor is occupied by maraviroc. It would almost certainly do the same for ligands like CCL5 (RANTES) etc. Leronlimab blocks binding of other proteins by binding deep in the CCR5 receptor including at the n terminal which is used by all ligands that bind to CCR5 and blocks them completely. The n terminal is why I refuted Cytodyn's claim that leronlimab did not block the CCR5 ligands.